Weight-Based and Fixed-Dose Pembrolizumab Show Comparable Effectiveness in NSCLC

Summary: Doctors looked at two ways to give a lung cancer drug called pembrolizumab: a "one-size-fits-all" fixed dose, and a custom dose based on the patient's weight. They found that both ways work just as well to fight cancer and are equally safe. However, the weight-based dose is much cheaper. It also helps prevent giving too much medicine to people who weigh less. This is important because fixed doses are usually based on average American weights. Using weight-based doses could save money and help patients all over the world get the right, safe amount of medicine without overpaying.

For more details, see rssapp-oncologynurseadvisor-com at oncologynurseadvisor.com/news/weight-based-and-fixed-dose-pembrolizumab-show-comparable-effectiveness-in-nsclc/ (opens in new tab)